ABSTRACT
ABSTRACT BACKGROUND: Obese adolescents are at higher risk of development of cardiovascular risk factors and obesity in later life. Dietary intake of antioxidants, particularly curcumin, as an active ingredient of turmeric extract, may have noticeable effects on obesity and its important complications such as cardiovascular risk factors. Therefore, the aim of this study was to assess the effects of curcumin supplementation on cardiovascular risk factors among overweight and obese female adolescents. DESIGN AND SETTING: Randomized placebo-controlled clinical trial; Pediatric Cardiovascular Research Center, Isfahan, Iran. METHODS: 60 adolescent girls (aged 13-18 years) were randomly assigned to receive either placebo or intervention. The adolescents were asked to consume one 500 mg tablet per day, containing either standardized 95% turmeric extract or placebo, and to undergo a weight maintenance or a mild weight loss diet for 10 weeks. Anthropometric and biochemical indices were assessed at the baseline and the end of the intervention. RESULTS: Curcumin supplementation had beneficial effects on body mass index (P = 0.019), waist circumference (P = 0.008), hip circumference (P = 0.030), high-density lipoprotein levels (P = 0.042) and triglyceride/high-density lipoprotein ratio (P = 0.021). However, in univariate analysis of covariance, no significant differences were found between the intervention and placebo groups after 10 weeks of supplementation (P > 0.05). CONCLUSIONS: Prescription of curcumin supplementation along with use of a slight weight loss diet might have beneficial effects on some cardiovascular risk factors among overweight and obese female adolescents. Larger clinical trials with higher curcumin doses and longer duration are needed to confirm the results from the current study. CLINICAL TRIAL REGISTRATION: IRCT20171107037302N1
Subject(s)
Humans , Female , Adolescent , Body Composition/drug effects , Cardiovascular Diseases/etiology , Cardiovascular System/drug effects , Curcumin/administration & dosage , Overweight/metabolism , Blood Glucose/metabolism , Blood Pressure/drug effects , Exercise/physiology , Body Mass Index , Risk Factors , Dietary Supplements/analysis , Diet, Reducing , Waist Circumference , Lipids/blood , Obesity/complications , Obesity/metabolismABSTRACT
La práctica de restricción alimentaria intermitente (RAI) bien como sus variaciones, es utilizada por individuos con intensión de pérdida de masa corporal. Existen evidencias científicas favorables a esta práctica; no obstante, son insuficientes los estudios que muestren las consecuencias a largo plazo y sus repercusiones en el control de la homeostasis energética en el sistema nervioso central (SNC). Considerando su creciente utilización, tanto como su recomendación y además de la controversia existente en la bibliografía, la presente revisión tiene como objetivo mostrar los efectos de la RAI sobre la regulación central de la homeostasis energética registrados en la literatura.
The practice of intermittent food restriction (IFR) along its variations, is used by individuals with an intentional loss of body mass. There is scientific evidence favorable to this practice; however, studies showing the long term consequences and their impact on the control of energy homeostasis at the level of the central nervous system (CNS) are insufficient. Considering the increase in its use, as well as in its recommendation and the great controversy existing in the bibliography, the present review aims to show the effects of RAI on the central regulation of energy homeostasis reported in the literature.
ABSTRACT
Cardiovascular alterations are part of the obesity-related metabolic syndrome. The objective of this study was to verify the effect of sibutramine on obese patients heart rate. Systematic review of randomized clinical trials performed in the Brazilian Cochrane center, in obese patients, on use of sibutramine or placebo. Outcome: change in heart rate. Electronic database searched: Cochrane library, Medline, LILACS, Pubmed. There were no language, date, or other restrictions. Two reviewers made data collection and extraction, who independently obtained full articles of all eligible papers. Four studies provided dichotomous data for a meta-analysis, the outcome of which was favorable to placebo: relative risk (RR) 3.73, confidence interval (CI) 2.07 to 6.73, risk difference (RD) of 0.13, number needed to harm (NNH) of 7. Ten studies presented continuous data for a meta-analysis, the result of which was favorable to placebo: mean difference (MD) of 7.24, CI of 6.22-8.26. The use of sibutramine in obese patients significantly affects the heart rate.
Alterações cardiovasculares são parte da síndrome metabólica relacionada à obesidade. O objetivo deste estudo foi verificar a influência da sibutramina sobre a frequência cardíaca em pacientes obesos.Revisão sistemática de ensaios clínicos randomizados realizados no centro Cochrane do Brasil em pacientes obesos em uso de sibutramina ou placebo. Desfecho: alteração da frequência cardíaca. Banco de dados eletrônico pesquisados: Cochrane Library, Medline, LILACS, Pubmed. Não houve restrições quanto a idioma, data, ou outras restrições. Coleta de dados e extração foi realizada por dois revisores, que de forma independente obteve artigos na íntegra de todos os estudos elegíveis. Quatro estudos forneceram dados dicotômicos para uma meta-análise, cujo resultado foi favorável ao placebo:risco relativo (RR) 3,73, intervalo de confiança (IC) 2,07-6,73, diferença de risco (DR) de 0.13, número necessário para causar lesão (NNL) de 7. Dez estudos apresentaram dados contínuos para uma metanálise, cujo resultado foi favorável ao placebo: diferença média (DM) de 7,24, IC de 6,22-8,26. O uso da sibutramina em pacientes obesos afeta significativamente a frequência cardíaca.